Executive Summary: Which are the Top 10 New Pharma Automation Companies to Watch?  Synfini (USA) develops AI-driven chemistry automation that combines molecular design with robotic synthesis to speed up drug discovery.  ExtensityAI (Austria) – builds drug discovery automation using AI agents that scan literature, design experiments, and integrate directly into lab workflows.  Intrepid Labs (Canada) – creates a robotic drug formulation platform that uses machine learning to design and test optimized medicines with fewer experiments.  pixlbio (Sweden) – develops an AI-powered phenomics platform that analyzes cell images to predict drug mechanisms, targets, and toxicities.  Dash Bio (USA) – provides a clinical bioanalysis platform that uses robotics and techniques like ELISA, LC-MS, and qPCR for fast and reliable drug testing.  SmartLink (South Korea) – builds medical dispensing automation systems that measure, mix, and deliver reagents while streamlining DNA extraction and quality control.  Persist AI (USA) – develops an AI and robotics platform for drug formulation discovery, combining high-throughput labs with predictive models and cGMP manufacturing.  Spacebox (Germany) – creates an organ-on-chip platform that uses robotics and microfluidics to model diseases and improve drug testing.  SYDRA Biotech (Switzerland) – develops a robotic screening platform that combines AI and in vivo testing to discover molecules with aging-related benefits.  Fluidichem (France) – provides a flow chemistry robot that automates real-time synthesis and purification of compounds with AI-guided optimization.  Global Startup Heat Map highlights New Pharmaceutical Automation Companies to Watch  Through the Big Data & Artificial Intelligence (AI)-powered StartUs Insights Discovery Platform , covering over 9M+ startups, 20K+ technology trends, plus 150M+ patents, news articles & market reports, we identified the new pharma automation companies.  The Global Startup Heat Map below highlights emerging new pharma automation companies you should watch in 2026, as well as the geo-distribution of 210+ startups & scaleups we analyzed for this research.  According to our data, we observe high startup activity in the USA and India, followed by the UK. The top 5 Startup Hubs for new pharma automation companies are New York, Hyderabad, Pune, Ahmedabad, and London.  Discover New Pharma Automation Companies to Watch in 2026  We hand-picked startups to showcase in this report by filtering for their technology, founding year, location, funding, and other metrics. These emerging pharma automation companies work on solutions ranging from AI cloud foundry and robotic drug formulation to medical dispensing automation and robotic screening.  1. Synfini – AI-driven Chemistry Automation  Founding Year  Location : Menlo Park, California, USA  Funding USD 8.9 million  Prominent Partnerships Multispan O2nix Bio  US-based startup Synfini develops AI-driven chemistry automation that integrates virtual molecular design with robotic synthesis to accelerate drug discovery. Its platform, Synfini AI Cloud Foundry , applies generative algorithms to propose synthetically accessible molecules and organizes structured workflows to guide discovery programs.  Moreover, the platform integrates automated synthesis and testing with hosted models for target-specific exploration and evaluates compounds with precision. Further, it incorporates AI-guided multiparameter optimization to refine molecular properties across different stages of development. Thus, the startup streamlines the development of preclinical drug candidates for a faster and more cost-efficient route to new therapeutics.  2. ExtensityAI – Drug Discovery Automation  Founding Year  Location : Wels, Austria  Revenue:  EUR 1 million  Major clients Story.one Third Wish AI FH Oberosterreich  Austrian startup ExtensityAI specializes in drug discovery automation of complex research workflows in pharmaceutical robotics and drug discovery. The platform integrates networks of specialized AI agents with human scientists to accelerate pharmaceutical innovation. Moreover, it combines pattern recognition with symbolic reasoning for agents to trace evidence, test hypotheses, and explain conclusions.  The startup also embeds its systems into laboratory data pipelines to document transparent chains of reasoning and scale research without reducing rigor. Then, its agents scan scientific literature, identify knowledge gaps, design and simulate experiments, validate outcomes, and generate publication-ready reports. This reduces inefficiencies that drive drug development costs.  3. Intrepid Labs – Robotic Drug Formulation  Founding Year  Location : Toronto, Canada  Funding USD 7 million  Startup Stage Seed  Canadian startup Intrepid Labs creates a robotic drug formulation platform to accelerate the creation of optimized medicines. It applies ML with modular lab automation to design, prepare, and analyze multiple formulation candidates in parallel. This replaces inefficient design of experiment methods with informed iterations that generate accurate predictive models from limited training data.  Further, the platform reduces material use by producing optimized formulations with fewer experiments while incorporating downstream drug development measurements to strengthen results. As a result, it enables faster, more efficient, and resource-conscious drug product development.  4. pixlbio – AI-powered Phenomics  Founding Year  Location : Uppsala, Sweden  Swedish startup pixlbio develops an AI-driven drug discovery platform that integrates phenomics, automation, and advanced image analysis. The platform employs cell painting to generate high-content morphological profiles of cells by capturing intricate cellular signatures through organelle-specific fluorescent dyes and high-resolution imaging.  Additionally, these profiles feed into AI models, which analyze morphological changes induced by various perturbations to predict mechanisms of action, targets, and potential toxicities.  5. Dash Bio – Clinical Bioanalysis Platform  Founding Year  Location : Boston, Massachusetts, USA  Funding USD 11 million  Startup Stage Seed  US-based startup Dash Bio provides a clinical bioanalysis platform that utilizes robotics and automation to accelerate drug development. The platform processes assays through automated method development, validation, and high-throughput techniques like enzyme-linked immunosorbent assay (ELISA), liquid chromatography-mass spectrometry (LC-MS), and quantitative polymerase chain reaction (qPCR). This ensures precise and reproducible results across diverse modalities.  Also, the platform employs advanced chromatography, robotic sample preparation, and locked protocols with full audit trails to maintain accuracy and regulatory compliance. This reduces turnaround times compared to traditional methods, while enhancing both speed and quality without increasing costs.  Want to Explore 210+ Pharma Automation Startups & Scaleups?  Request Sample Database  6. SmartLink – Medical Dispensing Automation  Founding Year  Location : Incheon, South Korea  South Korean startup SmartLink specializes in medical dispensing automation for pharmaceutical, bio, and chemical industries. Its automated dispensing technology precisely measures, mixes, and delivers reagents while reducing manual handling and ensuring consistent experimental conditions.  Further, it integrates complementary bio automation devices like nucleic acid extractors, automated evaporators, and inspection systems. These devices streamline laboratory workflows from deoxyribonucleic acid (DNA) extraction to quality control. They utilize machine vision algorithms, precision control, and customizable hardware and software to ensure accuracy and adaptability.  7. Persist AI – AI-driven Robotics for Pharma Formulation  Founding Year  Location : West Sacramento, California, USA  Funding USD 12 million in Series A  Revenue : Reached USD 3.8 million in 2024  Prominent Partnerships : Nivagen Pharmaceuticals, Spero Ventures  US-based startup Persist AI develops an AI and robotics-driven platform for drug formulation discovery and manufacturing. It combines high-throughput robotic labs and ML models to predict, build, and analyze thousands of formulations in parallel. The platform integrates tools such as high-performance liquid chromatography (HPLC), Raman, and spectrophotometry to capture critical process parameters.  The platform allows scientists to remotely design experiments that robots execute. This generates data to refine AI predictions until a target product profile is achieved. Persist AI also provides analytical support, formulation development, and commercial current good manufacturing practice (cGMP) manufacturing to accelerate R&D, reduce costs, and bring therapies to market faster.  8. Spacebox – Organ-on-Chip Platform  Founding Year  Location : Cologne, Germany  German startup Spacebox develops an automated organ-on-chip platform that enables high-precision disease modelling for pharmaceutical research. The platform integrates microfluidic environments with robotics to replicate physiological conditions. This allows researchers to produce uniform spheroids and organoids for reliable drug testing.  Additionally, it incorporates customizable control mechanisms and intuitive software that streamline experimental workflows. This ensures compatibility with existing laboratory protocols while reducing manual intervention.  9. SYDRA Biotech – Robotic Screening  Founding Year  Location : Zurich, Switzerland  Prominent Partnerships : Venture Kick, Venturelab, NVIDIA, EWOR  Swiss startup SYDRA Biotech provides a robotic screening platform that utilizes artificial neural networks with autonomous in vivo testing to identify small molecules with geroprotective properties. It operates as a closed-loop discovery engine, where AI-driven predictions guide robotic experiments, and experimental outcomes continuously refine the models to accelerate drug discovery.  Moreover, the startup creates a robotic assistant that increases throughput, reduces costs, and improves the reliability of live screening. This scales geroprotector testing and shortens development timelines.  10. Fluidichem – Flow Chemistry Robot  Founding Year  Location : Mulhouse, France  French startup Fluidichem offers a synthesis robot to automate continuous flow chemistry for pharmaceutical applications. The robot feeds reagents into a compact reactor for real-time synthesis and purification of chemical compounds.  Moreover, it integrates AI to rapidly identify optimal reaction conditions for enhancing efficiency and precision. Its modular design allows for easy scalability and adaptation to various chemical processes.  Discover All Emerging Pharma Startups  The pharma startups showcased in this report are only a small sample of all startups we identified through our data-driven startup scouting approach. Download our free Pharma Innovation Report for a broad overview of the industry or get in touch for quick & exhaustive research on the latest technologies & emerging solutions that will impact your company in 2026!  Discover our Free Pharma Report  DOWNLOAD  Get free updates on Global Startups, Technologies & Trends!  Business Email  Get our free startup, tech, and trends newsletter.  Protected by reCAPTCHA. The Google Privacy Policy and Terms of Service apply. By submitting this form you agree to StartUs Insights' Data Protection.

10 New Pharma Automation Companies and Startups to Watch in 2026

SACRAMENTO, Calif., May 19, 2025 /PRNewswire/ — Persist AI, a pioneer in AI-driven robotics for pharmaceutical formulation development and Chemistry, Manufacturing, and Controls (CMC), today announced the launch of its innovative Cloud Lab platform following the successful closure of an oversubscribed $12 million Series A financing round. The new platform allows pharmaceutical companies to develop formulations using Persist AI's state-of-the-art robotic laboratory facilities through a website, dramatically accelerating drug development timelines while using a fraction of the materials required by traditional methods.  The funding round was led by Spero Ventures with participation from MBX Capital, Shimadzu Future Innovation Fund managed by Global Brain Corporation, Eli Lilly & Company, SignalFire, Ford Street Capital, Purdue Ventures, Good AI Capital, Cartography Capital, Asymmetry Ventures, and existing investors 2048 Ventures, Innospark, and YCombinator.  “Every drug that reaches the market depends on an optimal formulation. While the industry has heavily invested in AI and predictive tools across the drug development pipeline, formulation has remained a blind spot—until now.” said Sara Eshelman, General Partner at Spero Ventures. “Persist dramatically reduces both the time and cost at every stage of development, ultimately lowering the hurdle for investment in next-generation therapeutics like long-acting injectables.”  Predict the ideal formulation with Persist's AI models  Persist AI's technology enables pharmaceutical companies to predict formulation recipes and performance using sophisticated AI models and subsequently build and test them using robotic systems. In a recent project with a major pharmaceutical client, Persist AI demonstrated the power of its platform by identifying an optimal long-acting injectable formulation in just two months—a process that traditionally takes a year or longer. By rapidly building and testing 700 formulations in two months, compared to the industry standard of 10-15 formulations per month, Persist AI accelerates a critical phase in bringing new drugs to market.  “AI is enabling pharma to discover new molecules faster than ever. But a molecule that has poor shelf life cannot become a drug product that sits on a shelf. Our mission is to convert these novel molecules into products, such as tablets and injections that patients can use,” said Karthik Raman, CEO of Persist. “If you can find a new drug molecule, you can predict its formulation and use our robotic platform to build and test it in the real world.”  Persist Cloud Lab – A Robotic Lab to Build and Test Formulations Remotely  Once the AI models predict a set of formulations, Persist's Cloud Lab enables pharmaceutical scientists to test the formulation by remotely controlling the robotic lab. With a combination of miniaturization and seamless automation of formulation testing instruments, Persist's technology leads to an unprecedented speed advantage in drug development.  Traditional testing instruments often require large volumes of liquid and significant amounts of formulation material per test. As an example, a standard dissolution testing apparatus requires 1000 mL of liquid and several grams of formulation. In contrast, Persist's miniaturized systems can deliver results with just 1 mL of liquid and a few milligrams of material. This breakthrough not only conserves valuable drugs but also enables higher throughput testing.  “Persist AI has assembled a talented chemistry, engineering, and software team that develops exceptional automated solutions for formulation development workflows,” said Chris Shelner, COO of Persist. “We continue to improve our automation in addition to expanding capacity and workflow scope.”  Through the newly launched Cloud Lab, pharmaceutical companies worldwide can now remotely build and test formulations on Persist's advanced robotic facilities to develop:  Long acting injectables  Tablets and capsules  Topical formulations for cosmetics and pharmaceuticals  Injectable formulations  The platform supports a wide range of modalities including peptides, small molecules, antibodies, and anti-sense oligonucleotides, currently serving multiple top 10 pharmaceutical clients and several smaller biotechs developing next-generation treatments for chronic diseases.  Series A Funding to Accelerate Growth and Innovation  The $12 million in Series A funding will support several key initiatives. Persist will build a GMP manufacturing system for long acting injectables, in collaboration with Nivagen Pharmaceuticals in Sacramento, CA. Funds will be used to expand the robotic lab and build comprehensive data sets that train the company's AI models. Additionally, the team will expand the capacity and range of formulations the AI models and robotic lab can predict, build, and test.  Persist is actively seeking pharmaceutical partners for co-development of drug products, robotic platforms, and AI training data sets.  To learn more about Persist AI's Cloud Lab platform and request access, visit https://www.persist-ai.com . Pharmaceutical companies interested in partnership opportunities are encouraged to contact Karthik Raman via his email below or through the website.  About Persist AI  Persist AI is revolutionizing pharmaceutical development through AI-driven robotics for formulation development and CMC. By combining predictive AI models with automated robotic systems, Persist AI enables pharmaceutical companies to develop drug formulations in a fraction of the time and cost of traditional approaches. The company works across multiple modalities and formulation types to accelerate bringing novel therapeutics to patients. Persist AI is a Y Combinator-backed company, having graduated from the prestigious startup accelerator in 2023.  About the Leadership Team  Karthik Raman, CEO and Co-founder of Persist, brings extensive expertise in formulation development. Prior to founding Persist, Raman was part of the automation team at Zymergen, developing the next generation robotic factory for synthetic biology. Co-founder Christopher Shelner serves as Chief Operating Officer, with significant expertise in automation design, operations, and deployment from his work at industry leaders including Northrop Grumman and Apple.  SOURCE Persist AI Formulations  Copyright © 2025 Cision US Inc.

Persist AI Launches Cloud Lab to Accelerate Pharmaceutical Formulation Development, Raises $12M Series A Funding

2.00
Eli Lilly and Co. and Purdue Ventures recently participated in a $12 million funding round to support a new remote lab platform aimed at significantly decreasing the time it takes to research and develop new medicines. Sacramento, California-based Persist AI announced the funding round last week, as well as the launch of its new Cloud Lab platform, which allows pharmaceutical companies to develop formulations in their lab via the web. The platform’s goal is to accelerate development and reduce the amount of formulation materials required by more traditional methods. Pharmaceutical companies around the world can remotely access the Cloud Lab to test formulations to develop injectables, tablets and capsules and topical formulations. The funding round was led by Burlingame, California-based Spero Ventures, and nine other funders joined Purdue Ventures and Lilly in supporting. Persist did not share how much each funder contributed. Chad Pittman, president and CEO of Purdue Research Foundation, told IBJ in a written statement that Purdue Research Foundation made a “significant investment” in the funding round. “Given the company’s strong alignment with Purdue University’s areas of excellence, particularly in advanced pharmaceutical manufacturing and the application of digital twins and AI, our investment was a clear and simple choice,” Pittman said. Persist’s technology uses artificial intelligence to predict formulation recipes and allows pharmaceutical companies to test them using robotic systems. A recent project identified an injectable formulation in two months, according to Persist, compared to the industry standard of 10 to 15 months. During those two months, 700 formulations were built and tested. “AI is enabling pharma to discover new molecules faster than ever. But a molecule that has poor shelf life cannot become a drug product that sits on a shelf,” Persist CEO Karthik Raman said in a written statement. “If you can find a new drug molecule, you can predict its formulation and use our robotic platform to build and test it in the real world.”
Announced at the same time as the funding round, Persist’s Cloud Lab allows scientists to test their formulations by remotely controlling a robotic lab. Not only does the AI-assisted formulation process move more quickly, but the testing also uses a fraction of the formulation materials typically required. Instead of 1000 milliliters of liquid and several grams of formulation, the company says it can produce results with 1 milliliter and milligrams of a drug. “Every drug that reaches the market depends on an optimal formulation. While the industry has heavily invested in AI and predictive tools across the drug development pipeline, formulation has remained a blind spot—until now,” Sara Eshelman, general partner at Spero Ventures, said in a written statement. “Persist dramatically reduces both the time and cost at every stage of development, ultimately lowering the hurdle for investment in next-generation therapeutics like long-acting injectables.”
The Series A funding will support initiatives, including a manufacturing system for long-acting injectables, expanding the robotic lab and building data sets for the company’s AI models and expanding the capacity and range of formulations that the AI models and lab can predict, build and test. Persist AI graduated from the California-based Y Combinator accelerator in 2023. Story Continues Below

Lilly, Purdue Ventures invest in AI-assisted remote lab platform

News provided by
Share this article
Share toX
A roundup of the most newsworthy tech announcements from PR Newswire this week, including a new XR device for Android, Acer's new Copilot+ PCs and a tech tradeshow recap. NEW YORK, May 23, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help tech journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Embracing AI, a newly formed alliance of technology leaders, officially launched with a clear mission: to simplify and accelerate operational AI adoption for organizations of all sizes. Embracing AI is purpose-built to help companies turn their data into decision-ready insights while maintaining enterprise-grade security, reliability, and speed. A lightweight and tethered, cinematic, and Gemini AI-powered device, Project Aura brings a large field-of-view experience to the Android XR family — setting a new standard for immersive, wearable computing. Record-Breaking World Liberty Financial USD1 Stablecoin Unlocks Cross-Chain Capabilities With Chainlink  "Chainlink's battle-tested infrastructure delivers the institutional-grade security and extensive reach needed to deliver USD1 into the hands of millions across a growing number of active, onchain ecosystems. WLFI's partnership with Chainlink will accelerate and improve USD1's utility for cross-border payments and will result in truly useful applications across DeFi and traditional finance," said Zach Witkoff, co-founder of World Liberty Financial. Palantir and Divergent Form Partnership to Revolutionize On-Demand Advanced Manufacturing  With access to the Divergent Adaptive Production System (DAPS™) within Palantir's software, customers will be able to rapidly identify emerging supply chain vulnerabilities and then directly address them through on-demand manufacturing of critical parts by Divergent. Superna Launches Data Security Essentials for Dell PowerStore, Delivering Unified Protection for All File Data -- Including Windows Server Workloads  As ransomware attacks become more sophisticated and relentless, organizations need proactive defense that starts where attackers do — at the data layer. Superna's latest innovation for PowerStore delivers real-time visibility and control to reduce risk before an attack begins and stop threats the moment they strike. Persist AI Launches Cloud Lab to Accelerate Pharmaceutical Formulation Development, Raises $12M Series A Funding  The new platform allows pharmaceutical companies to develop formulations using Persist AI's state-of-the-art robotic laboratory facilities through a website, dramatically accelerating drug development timelines while using a fraction of the materials required by traditional methods. This innovative, AI-driven tool allows the public to easily search geo-targeted alerts sent through the ADAM Program (Automated Delivery of Alerts on Missing Children) and view missing child posters by location, and other filters. Frisco Unveils New Innovation Hub to Support Growing Innovation and Venture Capital Sectors  The facility is designed to bring industry specific accelerator programming, sports-tech innovation in human potential and international startup support to the region. " I'm excited to see the groundbreaking innovation that will take shape here," said Jeff Cheney, Mayor of Frisco, Texas. JetCool, a Flex Company, Launches New Liquid Cooling Systems Delivering 15% IT Power Savings Without Facility Upgrades  "With the new SmartPlate System, we're helping customers deploy more compute per rack in colocations and facilities that don't have water hookups, all while cutting power consumption and improving thermal performance," said Dr. Bernie Malouin, JetCool Founder and Flex Vice President. Muon Space Awarded Additional NRO Contract for Next Phase of Commercial Electro-Optical Capabilities  Muon Space's vertically integrated technology platform, Muon Halo™, provides end-to-end solutions from space-based sensing to advanced onboard processing. Designed to support a range of government and commercial applications, it facilitates missions that shape the future of national security and Earth observation. YUAN Unveils Next-Gen AI Robotics Powered by NVIDIA for Land, Sea & Air  With its Pandora NX Super and AIR NX Super platforms, YUAN, a pioneer in industrial video PCs, is revolutionizing autonomous decision-making and real-time video analytics. These advanced solutions bring groundbreaking innovations to maritime safety, agricultural optimization, and aerial inspections. Acer Debuts New Copilot+ PCs: Ultra-light Swift Edge AI and Everyday-Performer Swift Go AI  The new Swift Copilot+ PCs boast NPUs that perform over 40 TOPS and are equipped to run the most demanding AI workloads and offer exclusive AI experiences such as Recall (preview), Click to Do (preview), and improved Windows search, Cocreator, Live Captions, and Windows Studio Effects.

Weekly Recap: 15 Tech Press Releases You Need to See

The funds will be used to support building a GMP system for long-acting injectables and grow the company's robotic lab. Photo: poba/Getty Images
Persist AI, an AI-driven robotics platform for the pharmaceutical industry, announced an overscribed $12 million Series A funding round. Spero Ventures led the round with participation from MBX Capital, Shimadzu Future Innovation Fund managed by Global Brain Corporation, Eli Lilly & Company , SignalFire , Ford Street Capital, Purdue Ventures, Good AI Capital, Cartography Capital, Asymmetry Ventures and existing investors 2048 Ventures, Innospark and YCombinator . The company also announced the launch of its Cloud Lab platform, which enables pharmaceutical companies to develop formulations using Persist AI's state-of-the-art robotic laboratory facilities via a website. The aim is to expedite drug development timelines using a fragment of the materials required by traditional methods. WHAT IT DOES
Persist AI allows pharmaceutical companies to forecast formulation recipes and performance utilizing advanced AI models as well as build and test them with robotic systems. By incorporating predictive AI models with automated robotic systems, the company says pharmaceutical firms can develop drug formulations quickly and cost-effectively compared to traditional approaches. The funding will be used to build a manufacturing practice system for long-acting injectables in cooperation with Nivagen Pharmaceuticals. According to the company, the funds will also be used to grow its robotic lab, build thorough datasets to train its AI models, expand the size and scope of formulations the AI models and robotic lab can predict, build and test. "AI is enabling pharma to discover new molecules faster than ever," Karthik Raman, CEO of Persist, said in a statement. "But a molecule that has poor shelf life cannot become a drug product that sits on a shelf. Our mission is to convert these novel molecules into products, such as tablets and injections that patients can use. If you can find a new drug molecule, you can predict its formulation and use our robotic platform to build and test it in the real world." MARKET SNAPSHOT
In 2024, Persist AI and Nivagen collaborated to co-develop a next-generation manufacturing process for long-acting injectable drugs, using Persist's AI-based formulation technology and Nivagen's manufacturing capabilities. The partnership aimed to simplify and accelerate the development and approval of LAI drugs, which could provide sustained and controlled drug release over weeks or months, improving patient adherence and outcomes. That same year, Persist AI raised $4 million in a seed financing round led by 2048 Ventures, with participation from Innospark Ventures, Fellows Fund, Pioneer Fund, Y Combinator and  Jovono. Tags:

Persist AI secures $12M Series A Funding, unveiled Cloud Lab platform

Zymergen

Bio-Rad

Penumbra

The University of Utah

Recursion Pharmaceuticals

University of California San Diego

Digital Health 50: The most promising digital health startups of 2025

Book of Scouting Reports: AI in Preclinical Development

The AI in drug R&D market map

Y Combinator’s healthcare investment strategy prioritizes drug R&D, care delivery, and insurance

Y Combinator Winter 2023

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Digital Health

Artificial Intelligence (AI)

Digital Health 50

Convertible Note

Seed VC - II

Series A

Persist AI is a company specializing in AI-driven drug formulation development within the pharmaceutical industry. The company offers services such as high-throughput screening of drug formulations, cloud-based formulation laboratories, and automated aseptic manufacturing. Persist AI primarily serves drug manufacturers and contract research organizations (CROs) in the pharmaceutical sector. It was founded in 2022 and is based in West Sacramento, California.

Persist AI

Spero Ventures

2048 Ventures

Asymmetry Ventures

Cartography Capital

Eli Lilly and Company

Ford Street Capital

Global Brain

Good AI Capital

Innospark Ventures

MBX Capital

Purdue Ventures

SignalFire

Y Combinator

METiS Technologies engages in AI-driven drug formulation within the pharmaceutical industry. The company uses machine learning, quantum simulation, and high-throughput experimentation to develop drug candidates. METiS Technologies serves the pharmaceutical sector with a focus on drug formulation. It was founded in 2020 and is based in Hangzhou, China.

METiS Technologies

Dyno Therapeutics develops a biotechnology platform. It applies artificial intelligence (AI) and quantitative high-throughput in vivo experiments to develop gene therapy. It enables medical researchers to access novel adeno-associated virus (AAV) vectors, facilitating targeted delivery for new gene therapies. The company was founded in 2018 and is based in Watertown, Massachusetts.

Dyno Therapeutics

ViaNautis focuses on the development of genetic nanomedicines in the biotechnology industry. The company's main service involves using its technology a nanovesicle platform that uses advanced polymer materials and machine learning to direct nucleic acid therapeutics to specific sites of action, focusing on hard-to-reach areas such as the brain and lungs. ViaNautis formerly known as SomaServe. It was founded in 2018 and is based in Cambridge, United Kingdom.

ViaNautis

Mana.bio operates as an artificial intelligence-based drug delivery startup company. It creates a platform for Lipid Nanoparticle (LNP) development for oligonucleotide therapies including ribonucleic acid (RNA)-based therapeutics, vaccines, and gene therapy. The company uses technology powered by machine learning and nanotechnology to identify formulations of lipid nanoparticle drug delivery systems and focus on gene therapy. It was founded in 2021 and is based in Tel Aviv, Israel.

Mana.bio

Intrepid Labs serves as a biotechnology company focused on the development of therapeutics through technology. The company specializes in designing next-generation drug products using machine learning, robotics, and pharmaceutical expertise to enhance drug properties and performance. Intrepid Labs serves sectors within the pharmaceutical and biotechnology industries. It was founded in 2023 and is based in Toronto, Canada.

Intrepid Labs

The computational platforms for drug formulation market encompasses AI and machine learning platforms that optimize drug delivery systems and formulation design. These solutions focus on nanoparticle-based delivery design, tablet formulation optimization, high-throughput formulation screening, and solubility enhancement. Key technologies combine AI with advanced computational methods to enhance drug targeting, bioavailability, stability prediction, and manufacturing efficiency. This market primarily serves pharmaceutical companies and biotechnology firms developing novel drug delivery systems and formulations.

Name	Work History	Title	Status
Karthik Raman	Zymergen, Bio-Rad, Penumbra, The University of Utah, Recursion Pharmaceuticals, and University of California San Diego	Founder, Chief Executive Officer	Current
Subscribe to see more	Subscribe to see more	Subscribe to see more	Subscribe to see more

Name	Karthik Raman	Subscribe to see more
Work History	Zymergen, Bio-Rad, Penumbra, The University of Utah, Recursion Pharmaceuticals, and University of California San Diego	Subscribe to see more
Title	Founder, Chief Executive Officer	Subscribe to see more
Status	Current	Subscribe to see more

How VCs Use CB Insights

Professional Services

Platform Overview

Persist AI

Executives

Persist AI Management Team

2 Team Members